Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

Bain is closing its business in Johannesburg, likely bringing to an end a yearslong battle to try and restore its reputation.

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

Bain Capital’s exit leaves Perpetual negotiating with Oaktree-backed financial planner roll-up AZ Next Generation Advisory.

The three groups preparing to bid are Lone Star and Kenedix, Bain and Tokyu Fudosan, and KKR, PAG and Nomura Real Estate, two ...

Large private investment firm, Bain Capital, plans to sell its majority stake in an insurance broker and agency network based ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...